Skip to main content


Figure 1 | BMC Research Notes

Figure 1

From: Effects of 8,000 IU aXa long-term prophylaxis with certoparin on the incidence of hyperkalemia in patients with coronary heart disease – a post-hoc analysis of the PARAT trial

Figure 1

Serum potassium (mean ± standard deviation) with certoparin or placebo. Compared to baseline, there is a statistically significant increase of serum potassium in the treatment period in either group. Legend: n.s., non significant; the statistical evaluation was performed using paired, two sided t-test for each of the treatment groups to compare baseline and follow-up values.

Back to article page